FIELD: medicine; pharmaceuticals.
SUBSTANCE: following is proposed: the use of the ProAgio polypeptide, which specifically binds to integrin αvβ3 inβA-domain in the area α 2-helices, BC loops and loops α2-α3, for the prevention or treatment of liver fibrosis in a subject, wherein the said polypeptide has the following amino acid sequence SEQ ID NO: 2 and the following SEQ ID NO: 3. The following is proposed: a method of preventing or treating liver fibrosis in a subject comprising identification of a subject in need thereof and administering the said polypeptide to the said subject. The proposed group of inventions ensures the prevention of liver fibrosis by administering to the subject the ProAgio polypeptide, which specifically binds to integrin αvβ3 inβA-domain in the area α 2-helices, BC loops and loops α2-α3.
EFFECT: obtaining integrin-targeting protein.
16 cl, 57 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED THERAPY BY USING ANTIANGIOGENIC AGENTS AND TNF-ALPHA | 2002 |
|
RU2316337C2 |
| VERSIONS OF DISINTEGRIN AND THEIR PHARMACEUTICAL APPLICATION | 2015 |
|
RU2685869C1 |
| ANTAGONISTS OF ALPHAVBETA3 AND ALPHAVBETA6 INTEGRINS AND ANTIFIBROTIC AGENTS | 2004 |
|
RU2388472C2 |
| METHOD FOR INHIBITING CEREBRAL TUMORS GROWTH DUE TO SELECTED ANTAGONISTS OF INTEGRINS | 2000 |
|
RU2255765C2 |
| METHOD OF TREATMENT OF TUMORS | 2003 |
|
RU2323737C2 |
| METHODS AND COMPOSITION USEFUL FOR ANGIOGENESIS INHIBITION | 1995 |
|
RU2162712C2 |
| COMPOSITION AND METHOD FOR DOUBLE TARGETING IN TREATMENT OF NEURO-ENDOCRINE TUMORS | 2019 |
|
RU2789198C2 |
| COMBINED THERAPY WITH USING ALPHA5BETA1 ANTAGONISTS | 2007 |
|
RU2465282C2 |
| FUSED PROTEIN WITH EFFECT OF ANGIOGENESIS INHIBITOR | 2008 |
|
RU2372354C1 |
| METHODS OF USING INTERLEUKIN-10 FOR TREATING DISEASES AND DISORDERS | 2014 |
|
RU2679889C2 |
